论文部分内容阅读
在研究对产纳豆激酶的细菌进行筛选基础上,通过体外血凝块溶解实验、抗血凝实验和红细胞溶血实验,对不同菌株、不同酶活的纳豆激酶的溶栓、抗凝及溶血效果进行初步研究。研究结果显示:不同菌株纳豆激酶的体外溶栓和抗凝效果有很大差异;纳豆激酶酶活性对抗凝、溶栓和溶血效果有很大影响;与同等剂量的尿激酶相比,筛选出的自4、肽园等菌株所产纳豆激酶具有更强的抗凝和溶栓效果,而且安全性好,可望成为一种优良的新型溶栓制剂。
On the basis of the screening of natto kinase-producing bacteria, thrombolytic, anticoagulant and hemolysis of different strains and different natto kinases by in vitro clot lysis, anti-hemagglutination and erythrocyte hemolysis Effect of a preliminary study. The results showed that: the different strains of nattokinase in vitro thrombolysis and anticoagulant effect are very different; nattokinase activity on anticoagulant, thrombolysis and hemolysis have a great effect; with the same dose of urokinase, The selected from 4, peptide Park and other strains produced by natto kinase has a stronger anticoagulant and thrombolytic effect, and good safety, is expected to become a good new thrombolytic agents.